Liver involvement during visceral leishmaniasis;Place du foie dans la leishmaniose viscérale

Gastroenterologie Clinique et Biologique

Volumn 30, Issue 8-9, 2006, Pages 1027-1032

  Gangneux, Jean Pierre ^a,c   Donaghy, Ludovic ^a   Marty, Pierre ^b  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c Inst de Rech Contre le Cancer IRCC   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; STIBOGLUCONATE SODIUM;

CELLULAR IMMUNITY; CLINICAL FEATURE; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; HEMAGGLUTINATION; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOFLUORESCENCE; LEISHMANIA DONOVANI; LIVER; LIVER GRANULOMA; PARASITOSIS; REVIEW; SEROLOGY; VISCERAL LEISHMANIASIS; WESTERN BLOTTING;

EID: 33750697952     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(06)73378-4     Document Type: Review

References (34)

1. Bogdan C, Rollinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. Int J Parasitol 1998;28:121-34.
2. Blackwell JM. Genetic susceptibility to leishmanial infections: studies in mice and man. Parasitology 1996;112(Suppl):S67-74.
3. Leclercq V, Lebastard M, Belkaid Y, Louis J, Milon G. The outcome of the parasitic process initiated by Leishmania infantum in laboratory mice: a tissue-dependent pattern controlled by the Lsh and MHC loci. J Immunol 1996;157:4537-45.
4. Gangneux JP, Sulahian A, Honore S, Meneceur P, Derouin F, Garin YJ. Evidence for determining parasitic factors in addition to host genetics and immune status in the outcome of murine Leishmania infantum visceral leishmaniasis. Parasite Immunol 2000;22:515-9.
5. Dedet JP. Données récentes sur les leishmanioses. Presse Med 2000;29:1019-26.
6. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002;2:494-501.
7. Rosenthal E, Marty P, Del Giudice P, Pradier C, Ceppi C, Gastaut JA, et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis 2000;31:1093-5.
8. Basset D, Faraut F, Marty P, Dereure J, Rosenthal E, et al. Visceral leishmaniasis in organ transplant recipients: 11 new cases and a review of the literature. Microbes Infect 2005;7:1370-5.
9. Coulibaly E, Heinis V, Campos C, Ozon C, Bourdoiseau G, Haas P, et al. Enquête descriptive sur la leishmaniose canine dans le Sud de la France en 2000. Prat Méd Chir Anim Comp 2004;39:35-40.
10. Basset D, Pratlong F, Ravel C, Dedet JP. Les leishmanioses autochtones et d'importation en France pour l'année 2000. In : Surveillance nationale des maladies infectieuses 1998-2000. Institut de Veille Sanitaire, Paris, 2003 : 215-7.
11. Gangneux JP, Menotti J, Lorenzo F, Sarfati C, Blanche H, Bui H, et al. Prospective value of PCR amplification and sequencing for diagnosis and typing of old world Leishmania infections in an area of nonendemicity. J Clin Microbiol 2003;41:1419-22.
12. Fissore C, Delaunay P, Ferrua B, Rosenthal E, Del Giudice P, Aufeuvre JP, et al. Convenience of serum for visceral leishmaniasis diagnosis by PCR. J Clin Microbiol 2004;42:5332-3.
13. Khaldi F, Bennaceur B, Ben Othman H, Achouri E, Ayachi R, Regaieg R. Atteinte hépatique sévère au cours de la leishmaniose viscérale : À propos de 7 cas. Arch Fr Pediatr 1990;47:257-60.
14. Albertini M, Leger I, Marty P, Gari-Toussaint M, Mary C, Saint Paul MC, et al. Leishmaniose viscérale sévère avec atteinte hépatique. Valeur diagnostique de la sérologie par immunoblot. Pediatrie 1993;48:377-80.
15. el Hag I, Hashim F, el Toum I, Homeida M, el Kalifa M, el Hassan A. Liver morphology and function in visceral leishmaniasis (Kala-azar). J Clin Pathol 1994;47:547-51.
16. Kausalya S, Malla N, Ganguly NK, Mahajan RC. Leishmania donovani: in vitro evidence of hepatocyte damage by Kupffer cells and immigrant macrophages in a murine model. Exp Parasitol 1993;77:326-33.
17. Gangneux JP, Lemenand O, Rheinard Y, Guiguen C, Guguen-Guillouzo C, Gripon P. In vitro and ex vivo permissivity of hepatocytes for Leishmania donovani. J Eukaryot Microbiol 2005;52:489-91.
18. Angarano G, Maggi P, Rollo M, Larocca A, Quarto M, Scalone A, et al. Diffuse necrotic hepatic lesions due to visceral leishmaniasis in AIDS. J Infect 1998;36:167-9.
19. Tafuri WL, de Oliveira MR, Melo MN. Canine visceral leishmaniosis: a remarkable histopathological picture of one case reported from Brazil. Vet Parasitol 2001;96:203-12.
20. Duarte MI, Corbett CE. Histopathological patterns of the liver involvement in visceral leishmaniasis. Rev Inst Med Trop Sao Paulo 1987;29:131-6.
21. Knolle PA, Gerken G. Local control of the immune response in the liver. Immunol Rev 2000;174:21-34.
22. Mehal WZ, Azzaroli F, Crispe IN. Immunology of the healthy liver: old questions and new insights. Gastroenterology 2001;120:250-60.
23. Goddard S, Youster J, Morgan E, Adams DH. Interleukin-10 secretion differentiates dendritic cells from human liver and skin. Am J Pathol 2004;164:511-9.
24. Rialland M, Corlu A, Ilyin G, Cabillic F, Lamy I, Guguen-Guillouzo C. Pattern of cytokine expression by rat liver epithelial cells supporting long-term culture of human CD34(+)umbilical cord blood cells. Cytokine 2000;12:951-9.
25. Murray HW. Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1 -dependent and -independent regulation. Infect Immun 2000;68:6294-9.
26. Engwerda C, Kaye P. Organ-specific immune responses associated with infectious disease. Immunol Today 2000;21:73-8.
27. Murray HW, Nathan CF. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 1999;189:741-6.
28. Murray HW. Tissue granuloma structure-function in experimental visceral leishmaniasis. Int J Exp Pathol 2001;82:249-67.
29. Gutierrez Y, Maksem JA, Reiner NE. Pathologic changes in murine leishmaniasis (Leishmania donovani) with special reference to the dynamics of granuloma formation in the liver. Am J Pathol 1984;114:222-30.
30. Murray HW, Stern JJ, Welte K, Rubin BY, Carriero SM, Nathan CF. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J Immunol 1987;138:2290-7.
31. Murray HW, Squires KE, Miralles CD, Stoeckle MY, Granger AM, Granelli-Piperno A, et al. Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity. J Immunol 1992;148:1858-63.
32. Gradoni L, Bryceson A, Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 1995;73:191-7.
33. Berman J. Miltefosine to treat leishmaniasis. Expert Opin Pharmacother 2005;6:1381-8.
34. Gangneux JP. Modalités récentes du traitement de la leishmaniose viscérale. Presse Med 1999;28:2057-66.